Transcriptional dysregulation is a hallmark of cancer and is frequently driven by oncogenic alterations that rewire downstream gene-expression programmes. Although kinase inhibitors targeting upstream oncogenic drivers can produce clinical benefit, responses are often limited by acquired resistance and pathway adapta...
Janice Wenzheng Neng, Laura Blenkarn, Laura S. Itzhaki et al.· Clinical Cancer Research· 0 citations
Targeted protein degradation is a potent strategy against intracellular proteins impervious to traditional drugs. We describe a platform reliant on high-throughput cloning and mRNA-based delivery to quickly screen 100s-1000s of modular biological degraders, which we challenge against the high-turnover c-Myc oncoprotein...
C. Ascanelli, Samuel Gilberto, C. Batho et al.· bioRxiv· 0 citations
It is demonstrated that selective degradation of CCNT1 can effectively collapse pTEFb-dependent transcriptional programmes and compromise tumour cell fitness, which may offer a more selective and durable route for therapeutic intervention in transcriptionally dependent tumours.
Janice Wenzheng Neng, Laura Blenkarn, Laura S. Itzhaki et al.· Clinical Cancer Research· 0 citations
The versatility of the assay is demonstrated and a 4-fold reduction in 5' cap concentration for in vitro transcription results in equivalent translation in cellulo, illustrating how split luminescent tagging can be easily integrated into the mRNA therapeutic workflow, enabling monitoring of real-time mRNA-driven protei...
C. Batho, Camilla Ascanelli, Megan L. Maple et al.· Journal of Visualized Experi...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
